Cardiovascular risk assessment and management in mental health clients: Perceptions of mental health and general practitioners in New Zealand

Journal of Primary Health Care

Volumn 1, Issue 1, 2009, Pages 11-19

  Wheeler, Amanda ^a,b   Harrison, Jeff ^a,b   Homes, Zara ^b  

^a WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^b THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cardiovascular risk; Mental health; Risk reduction

Indexed keywords

ARTICLE; ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASE; DISEASE MANAGEMENT; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HEALTH PERSONNEL ATTITUDE; HUMAN; INTERPERSONAL COMMUNICATION; MENTAL DISEASE; NEW ZEALAND; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; RISK ASSESSMENT;

ATTITUDE OF HEALTH PERSONNEL; CARDIOVASCULAR DISEASES; COMMUNICATION; DISEASE MANAGEMENT; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HUMANS; MENTAL DISORDERS; NEW ZEALAND; PHYSICIANS, FAMILY; PROFESSIONAL ROLE; RISK ASSESSMENT;

EID: 77954877332     PISSN: 11726164     EISSN: 11726156     Source Type: Journal    
DOI: 10.1071/hc09011     Document Type: Article

References (41)

1. Dickey B, Normand SL, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv 2002;53(7):861-7.
2. Sokal J, Messias E, Dickerson FB, Kreyenbuhl J, Brown CH, Goldberg RW, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis 2004;192(6):421-7.
3. Scott KM, Oakley Browne MA, McGee MA, Wells JE. Mental-physical comorbidity in Te Rau Hinengaro: The New Zealand Mental Health Survey. Aust NZ J Psychiatry 2006;40(10):882-8.
4. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11-53.
5. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58(9):844-50.
6. Weeke A, Juel K, Vaeth M. Cardiovascular death and manic-depressive psychosis. J Affect Disord 1987;13(3):287-92.
7. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45(1-2):21-8.
8. Brown S. Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry 1997;171:502-8.
9. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry 2007;64(2):242-9.
10. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004;192(1):19-27.
11. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150(6):1115-21.
12. Lambert TJR, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003;178(9 (Suppl):s67-s70.
13. Kendrick T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br J Psychiatry 1996;169(6):733-9.
14. Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001;35(2):196-202.
15. Ryan MCM, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002;71(3):239-57.
16. Basu R, Brar JS, Chengappa KNR, John V, Parepally H, Gershon S, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004;6(4):314-8.
17. Morriss R, Mohammed FA. Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol 2005;19(6_suppl):94-101.
18. Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust NZ J Psychiatry 2007;41(7):606-10.
19. Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 2005;48(2):215-21.
20. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70(1):1-17.
21. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005;19(SUPPL. 1):1-93.
22. Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004;74(16):1999-2008.
23. Sacchetti E, Turrina C, Parrinello G, Brignoli O, Stefanini G, Mazzaglia G. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int J Clin Psychopharmacol 2005;20(1):33-7.
24. Wang C-j, Zhang Z-j, Sun J, Zhang X-b, Mou X-d, Zhang X-r, et al. Serum free fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics. Biol Psychiatry 2006;60(12):1309-13.
25. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63(10):856-65.
26. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005;187:537-43.
27. Almeras N, Despres J-P, Villeneuve J, Demers M-F, Roy M-A, Cadrin C, et al. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004;65(4):557-64.
28. Ministry of Health. The New Zealand Health Strategy. Wellington, New Zealand: Ministry of Health; 2000.
29. New Zealand Mental Health Metabolic Working Group. Intervention Guide for Mental Health Service Users on Antipsychotic Therapy. Auckland: Janssen Cilag NZ Ltd; 2006.
30. Walker RA, Martin S. Demographic Profile for Waitemata District Health Board: An Analysis of 2006 Census. Auckland: Watemata District Health Board; 2007.
31. Breum L, Astrup A, Gram L, Andersen T, Stokholm KH, Christensen NJ, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992;41(6):666-70.
32. Vendsborg PB, Bech P, Rafaelsen OJ. Lithium treatment and weight gain. Acta Psychiatr Scand 1976;53(2):139-47.
33. New Zealand Mental Health Metabolic Working Group. A New Zealand Mental Health Metabolic Working Group Initiative. Auckland: Janssen Cilag Ltd; 2006.
34. New Zealand Guidelines Group. The assessment and management of cardiovascular risk: Evidence-based best practice guideline. Wellington: New Zealand Guidelines Group (NZGG); 2003.
35. New Zealand Guidelines Group. Management of Type 2 Diabetes: Evidence-based best practice guideline. Wellington: New Zealand Guidelines Group (NZGG); 2003.
36. Wells JE, Browne MAO, Scott KM, McGee MA, Baxter J, Kokaua J. Te Rau Hinengaro: The New Zealand Mental Health Survey: Overview of methods and findings. 2006;40(10):835-44.
37. Wheeler A, Robinson E, Robinson G. Admissions to acute psychiatric inpatient services in Auckland, New Zealand: a demographic and diagnostic review. N Z Med J 2005;118(1226):U1752.
38. Edmonds LK, Williams S, Walsh AE. Trends in Maori mental health in Otago. Aust N Z J Psychiatry 2000;34(4):677-83.
39. Baxter J, Kokaua J, Wells JE, McGee MA, Browne MAO. Ethnic comparisons of the 12 month prevalence of mental disorders and treatment contact in Te Rau Hinengaro: The New Zealand Mental Health Survey. 2006;40(10):905-13.
40. Suppes T, McElroy SL, Hirschfeld RMA. Awareness of Metabolic Concerns and Perceived Impact of Pharmacotherapy in Patients with Bipolar Disorder: A Survey of 500 US Psychiatrists. Psychopharmacol Bull 2007;40(2):22-37.
41. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. 2004;24(5 Suppl 1):S1-6.